NCT03111992View on ClinicalTrials.gov

Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

December 18, 2017

Primary Completion Date

March 2, 2020

Study Completion Date

March 2, 2020

Conditions
Multiple Myeloma
Interventions
DRUG

PDR001

Anti-PD1 antibody

DRUG

CJM112

Anti-IL-17A antibody

DRUG

LCL161

Oral small molecule SMAC-mimetic

Trial Locations (8)

20133

Novartis Investigative Site, Milan

24105

Novartis Investigative Site, Kiel

28006

Novartis Investigative Site, Madrid

37007

Novartis Investigative Site, Salamanca

37203

Sarah Cannon Research Institute, Nashville

69120

Novartis Investigative Site, Heidelberg

79106

Novartis Investigative Site, Freiburg im Breisgau

85054

Mayo Clinic Arizona, Phoenix

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY